Literature DB >> 9168952

Dimethylfumarate is an inhibitor of cytokine-induced E-selectin, VCAM-1, and ICAM-1 expression in human endothelial cells.

M Vandermeeren1, S Janssens, M Borgers, J Geysen.   

Abstract

Most studies on the antipsoriatic mode of action of dimethylfumarate focused on its antiproliferative effects in keratinocytes. Because inflammatory skin diseases are associated with an upregulation of endothelial cell adhesion molecules and because the presence of inflammatory cells in dermis and epidermis is considered an important feature in psoriasis, we tested the effect of DMF on cytokine-induced adhesion molecule expression in HUVEC, using in situ ELISA and Northern blotting. Dimethylfumarate inhibited ICAM-1, VCAM-1, and E-selectin expression and reduced adhesion of U937 cells to stimulated HUVEC. Monoethylfumarate and fumaric acid had no effect. Similar inhibitory effects for DMF on VCAM-1 expression were observed after stimulation of HUVEC with LPS, PMA, IL-4, and IL-1 alpha or in combinations with TNF alpha. These data are in agreement with previously reported effects of DMF on intracellular thiol levels and inhibition of NF-kappa B activation. The inhibitory effect on cytokine-induced endothelial adhesion molecule expression may represent another target of dimethylfumarate in psoriasis.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9168952     DOI: 10.1006/bbrc.1997.6570

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  36 in total

Review 1.  A mechanistically novel, first oral therapy for multiple sclerosis: the development of fingolimod (FTY720, Gilenya).

Authors:  Jerold Chun; Volker Brinkmann
Journal:  Discov Med       Date:  2011-09       Impact factor: 2.970

2.  Inhibitory effects of corni fructus extract on angiogenesis and adipogenesis.

Authors:  Jae-Ho Hwang; Jong-Deog Kim
Journal:  Korean J Physiol Pharmacol       Date:  2011-02-28       Impact factor: 2.016

3.  Analysis of Lymphocyte Extravasation Using an In Vitro Model of the Human Blood-brain Barrier.

Authors:  Andreas Schulte-Mecklenbeck; Urvashi Bhatia; Tilman Schneider-Hohendorf; Nicholas Schwab; Heinz Wiendl; Catharina C Gross
Journal:  J Vis Exp       Date:  2017-04-05       Impact factor: 1.355

4.  Ulcerated necrobiosis lipoidica as a rare cause for chronic leg ulcers: case report series of ten patients.

Authors:  Cindy Franklin; Maren Stoffels-Weindorf; Uwe Hillen; Joachim Dissemond
Journal:  Int Wound J       Date:  2013-10-07       Impact factor: 3.315

Review 5.  Vascular cell adhesion molecule-1 expression and signaling during disease: regulation by reactive oxygen species and antioxidants.

Authors:  Joan M Cook-Mills; Michelle E Marchese; Hiam Abdala-Valencia
Journal:  Antioxid Redox Signal       Date:  2011-05-11       Impact factor: 8.401

6.  Improvement of herpetic stromal keratitis with fumaric acid derivate is associated with systemic induction of T helper 2 cytokines.

Authors:  A Heiligenhaus; H Li; A Schmitz; S Wasmuth; D Bauer
Journal:  Clin Exp Immunol       Date:  2005-10       Impact factor: 4.330

7.  Influence of dimethylfumarate on experimental HSV-1 necrotizing keratitis.

Authors:  A Heiligenhaus; H Li; S Wasmuth; D Bauer
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2004-07-06       Impact factor: 3.117

8.  Fumaric Acid and its esters: an emerging treatment for multiple sclerosis.

Authors:  D Moharregh-Khiabani; R A Linker; R Gold; M Stangel
Journal:  Curr Neuropharmacol       Date:  2009-03       Impact factor: 7.363

Review 9.  A molecule solves psoriasis? Systemic therapies for psoriasis inducing interleukin 4 and Th2 responses.

Authors:  Kamran Ghoreschi; Ulrich Mrowietz; Martin Röcken
Journal:  J Mol Med (Berl)       Date:  2003-07-18       Impact factor: 4.599

Review 10.  Risk Mitigation Strategies for Adverse Reactions Associated with the Disease-Modifying Drugs in Multiple Sclerosis.

Authors:  Adnan M Subei; Daniel Ontaneda
Journal:  CNS Drugs       Date:  2015-09       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.